An evaluation of levalbuterol HFA in the prevention of exercise-induced bronchospasm

Journal of Asthma

Volumn 44, Issue 9, 2007, Pages 729-733

  Pearlman, D S ^a   Rees, William ^b   Schaefer, Kendyl ^c   Huang, Holly ^c   Andrews, William T ^c  

^a Respiratory Institute   (United States)

^b PI Coor Clinical Research LLC   (United States)

^c DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

2 agonist; Efficacy; Exercise induced bronchospasm; Levalbuterol HFA; Metered dose inhaler (MDI)

Indexed keywords

BECLOMETASONE; FLUORINATED HYDROCARBON; FLUTICASONE; LEVALBUTEROL; PLACEBO;

ADULT; ARTICLE; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; TREADMILL EXERCISE; TREATMENT DURATION;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ASTHMA, EXERCISE-INDUCED; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; METERED DOSE INHALERS; SPIROMETRY;

EID: 36248962117     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1080/02770900701595667     Document Type: Article

References (33)

1. Parsons JP, Mastronarde JG. Exercise-induced bronchoconstriction in athletes. Chest 2005; 128:3966-3974.
2. Anderson SD, Caillaud C, Brannan JD. Beta2-agonists and exercise-induced asthma. Clin Rev Allergy Immunol 2006;31:163-180.
3. Clark CJ, Cochrane LM. Physical activity and asthma. Curr Opin Pulm Med 1999;5:68-75.
4. Meyer R, Kroner-Herwig B, Sporkel H. The effect of exercise and induced expectations on visceral perception in asthmatic patients. J Psychosom Res 1990;34:455-460.
5. Ergood JS, Epstein LH, Ackerman M, Fireman P. Perception of expiratory flow by asthmatics and non-asthmatics during rest and exercise. Health Psychol 1985;4:545-554.
6. Panditi S, Silverman M. Perception of exercise induced asthma by children and their parents. Arch Dis Child 2003;88:807-811.
7. NHLBI. Guidelines for the diagnosis and management of asthma. National Institutes of Health; 1997. Report: 97-4051.
8. Penn RB, Frielle T, McCullough JR, Aberg G, Benovic JL. Comparison of R-, S-, and RS-albuterol interaction with human beta 1- and beta 2-adrenergic receptors. Clin Rev Allergy Immunol 1996;14:37-45.
9. Lotvall J, Palmqvist M, Arvidsson P, Maloney A, Ventresca GP, Ward J. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 2001;108:726-731.
10. Milgrom H. Levosalbutamol in the treatment of asthma. Expert Opin Pharmacother 2006;7:1659-1668.
11. Berkowitz R, Schwartz E, Bukstein D, Grunstein M, Chai H. Albuterol protects against exercise-induced asthma longer than metaproterenol sulfate. Pediatrics 1986;77:173-178.
12. Hawksworth RJ, Sykes AP, Faris M, Mant T, Lee TH. Albuterol HFA is as effective as albuterol CFC in preventing exercise-induced bronchoconstriction. Ann Allergy Asthma Immunol 2002;88:473-477.
13. Shapiro GS, Yegen U, Xiang J, Kottakis J, Della CG. A randomized, double-blind, single-dose, crossover clinical trial of the onset and duration of protection from exercise-induced bronchoconstriction by formoterol and albuterol. Clin Ther 2002;24:2077-2087.
14. Sichletidis L, Daskalopoulou E, Kyriazis G, Kosmidou I, Koupidou S, Pechlivanidis T, Chloros D. Comparative efficacy of salbutamol and salmeterol in exercise-induced asthma. J Int Med Res 1993;21:81-88.
15. Inman M, O'Byrne P. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am J Respir Crit Care Med 1996;153:65-69.
16. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, McKay RT, Wanger JS, Anderson SD, Cockcroft DW, Fish JE, Sterk PJ. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, 1999. Am J Respir Crit Care Med 2000;161:309-329.
17. U.S. Department of Health and Human Services FC. Guidance for Industry;Exercise-induced bronchospasm (EIB) - development of drugs to prevent EIB (draft). 2002.
18. McFadden ER Jr, Gilbert IA. Exercise-induced asthma. N Engl J Med 1994;12;330:1362-1367.
19. Jones B, Kenward M. Design and analysis of cross-over trials (monographs on statistics and applied probability). 2nd ed. Boca Raton, FL: Chapman & Hall; 2003.
20. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS systems for mixed models. Cary, NC: SAS Publishing; 1996.
21. Sterk PJ, Fabbri LM, Quanjer PH, Cockcroft DW, O'Byrne PM, Anderson SD, Juniper EF, Malo JL. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:53-83.
22. Anderson SD, Lambert S, Brannan JD, Wood RJ, Koskela H, Morton AR, Fitch KD. Laboratory protocol for exercise asthma to evaluate salbutamol given by two devices. Med Sci Sports Exerc 2001;33:893-900.
23. Task force on recognizing and diagnosing exercise-related asthma, respiratory and allergic disorder in sports. Evidence-based recommendations for the diagnosis of exercise-induced asthma in athletes. Eur Respir Mon 2005;33:102-104.
24. Senn SJ. The use of baselines in clinical trials of bronchodilators. Stat Med 1989;8:1339-1350.
25. Boner AL, Spezia E, Piovesan P, Chiocca E, Maiocchi G. Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children. Am J Respir Crit Care Med 1994;149(4 Pt 1):935-939.
26. Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 2006;117:18-24.
27. Hancox RJ, Subbarao P, Kamada D, Watson RM, Hargreave FE, Inman MD. Beta2-agonist tolerance and exercise-induced bronchospasm. Am J Respir Crit Care Med 2002;165:1068-1070.
28. Haney S, Hancox RJ. Rapid onset of tolerance to beta-agonist bronchodilation. Respir Med 2005;99:566-571.
29. Hayes MJ, Qing F, Rhodes CG, Rahman SU, Ind PW, Sriskandan S, Jones T, Hughes JM. In vivo quantification of human pulmonary beta-adrenoceptors: effect of beta-agonist therapy. Am J Respir Crit Care Med 1996;154:1277-1283.
30. Anderson SD. Single-dose agents in the prevention of exercise-induced asthma: a descriptive review. Treat Respir Med 2004;3:365-379.
31. Vathenen AS, Knox AJ, Wisniewski A, Tattersfield AE. Effect of inhaled budesonide on bronchial reactivity to histamine, exercise, and eucapnic dry air hyperventilation in patients with asthma. Thorax 1991;46:811-816.
32. Vidal C, Fernandez-Ovide E, Pineiro J, Nunez R, Gonzalez-Quintela A. Comparison of montelukast versus budesonide in the treatment of exercise-induced bronchoconstriction. Ann Allergy Asthma Immunol 2001;86:655-658.
33. Pedersen S, Hansen OR. Budesonide treatment of moderate and severe asthma in children: a dose-response study. J Allergy Clin Immunol 1995;95(1 Pt 1):29-33.